Trasylol aprotinin: Phase III discontinued

BAY discontinued 3 double-blind, placebo-controlled Phase III trials of Trasylol to reduce blood loss and the need for transfusions

Read the full 195 word article

How to gain access

Continue reading with a
two-week free trial.